Duong, Mai
Abouelfath, Abdelilah
Lassalle, Regis
Droz, Cécile
Blin, Patrick
Moore, Nicholas http://orcid.org/0000-0003-1212-2817
Funding for this research was provided by:
French Embassy, Hanoi
Article History
First Online: 24 May 2018
Compliance with Ethical Standards
:
: Mai Duong received a doctoral grant from the French Embassy in Hanoi.
: There are no conflicts of interest reported related to the present paper, which was funded internally by Bordeaux PharmacoEpi. Bordeaux PharmacoEpi is a public research platform of the University of Bordeaux and INSERM that has done many post-authorization studies over the years at the request of regulatory authorities, often funded by various pharmaceutical companies, but none to date concerning NSAIDs or their cardiovascular risks. Some of these studies concerned pharmaceutical companies that also manufacture NSAIDs or paracetamol. Nicholas Moore has in the past provided personal and consulting advice to pharmaceutical companies on post-authorization studies and the risks associated with NSAIDs or paracetamol, and as part of his work on data safety management boards. This includes manufacturers of ibuprofen, ketoprofen, diclofenac, naproxen, celecoxib, rofecoxib, and paracetamol, though none were involved in the present study. Mai Duong, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Patrick Blin have no conflicts of interest that are directly relevant to the content of this study. The present study was entirely initiated, designed, implemented and reported independently of any pharmaceutical company.
: This study used secondary anonymized data from the 1/97 sample of the French National Healthcare database, respecting all regulatory and legal requirements. By law, INSERM research teams can access that data without having to request further authorization from the national data protection committee, CNIL. The study protocol was deposited at INSERM before starting data access and extractions for a nihil obstat.